You searched for Caregiver

31 August 2023 - 2 mins read

Caring for a Loved One with Metastatic Pancreatic Cancer: Nora’s Story

Nora and her husband, Hector, met 39 years ago, got married shortly after, and have been inseparable ever since. In 2021, Hector was diagnosed with metastatic pancreatic cancer, which threw their entire family into navigating a very difficult diagnosis. No...

31 January 2024 - 4 mins read

Closing Gaps in Cancer Care – Together

Dr. Mónica de Abadal, Head of Medical Affairs, North America at Ipsen shares why she believes it takes everyone in the healthcare ecosystem coming together to close existing gaps and address health inequities in cancer care. ...

- 29 June 2023

Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva

PARIS, FRANCE, 29 June 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted in favor of investigational palovarotene as an effect...

- 24 June 2019

Ipsen Announces U.S. FDA Approval for Newly DesignedPre-Filled Syringe for Somatuline® Depot (lanreotide)

– New Syringe Designed to Help Enhance Injection Experience –Cambridge, Mass., June 24, 2019 – Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR:IPSEY), announced today that the United States Food and Drug Administration (FDA) has a...

- 16 March 2023

Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP

PARIS, FRANCE, 16 March 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) goal date, for the resubmitted New Drug Application (NDA) for investigational pa...

- 10 June 2024

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

PARIS, FRANCE, 10 June 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Iqirvo® (elafibranor) 80 mg tablets for the treatment of primary biliary cholangitis ...

- 13 February 2024

Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA

PARIS, FRANCE, 13 February 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application for Onivyde® (irinotecan liposome injection) plus oxaliplatin, fluorour...

- 26 April 2024 - 3 mins read

Measuring pancreatic cancer care in moments

Emad Abdelnaby, Senior Vice President, Oncology Franchise Head at Ipsen shares learnings from Dr. Maen Hussein of Florida Cancer Specialists & Research Institute about his approach to treating pancreatic cancer...

- 15 April 2024 - 3 mins read

Mighty bonds: Leaning on others living with FOP

Carli and Erin, cross-country best friends, discuss how they’ve realized the importance of a strong support network of immediate family and friends, along with people who have a shared experience of living with FOP. Their connections have been key to nav...

- 25 January 2022 - 2 mins read

Our pledge: summaries in plain language for all journal publications

Today, we are broadening our commitment to providing everyone with the opportunity to read and understand our research. From July 2022, we will publish, as a minimum, a 250-word plain language summary alongside all company-sponsored journal publications fr...

1 2

Search results